cancer
J Exp Med. 2005 Mar 7;201(5):779-91. Links
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX.
The Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
pingyu@uchicago.edu
Tumor environment can be critical for preventing the immunological destruction of antigenic tumors. We have observed a selective accumulation of CD4(+)CD25(+) T cells inside tumors. In a murine fibrosarcoma L(d)-expressing Ag104, these cells made up the majority of tumor-infiltrating lymphocytes at the late stage of tumor progression, and their depletion during the effector phase, rather than priming phase, successfully enhanced antitumor immunity. We show here that CD4(+)CD25(+) T cells suppressed the proliferation and interferon-gamma production of CD8(+) T cells in vivo at the local tumor site. Blockade of the effects of IL-10 and TGF-beta partially reversed the suppression imposed by the CD4(+) cells. Furthermore, local depletion of CD4(+) cells inside the tumor resulted in a change of cytokine milieu and led to the eradication of well-established highly aggressive tumors and the development of long-term antitumor memory. Therefore, CD4(+)CD25(+) T cells maintained an environment in the tumor that concealed the immunogenicity of tumor cells to permit progressive growth of antigenic tumors. Our study illustrates that the suppression of antitumor immunity by regulatory T cells occurs predominantly at the tumor site, and that local reversal of suppression, even at a late stage of tumor development, can be an effective treatment for well-established cancers.
PMID: 15753211 [PubMed - indexed for MEDLINE]
go to Google, enter ENTREZ PUBMD and fill in the PMID # into the rectangle
These regulatory T cells are the ones which use FOXP3, which is an Xlinked gene which seems to be tied to her2+ breast cancer, at least some of the familial variety and perhaps more
Linear Mode
